-- Dimerix（ASX：DXB）周二向澳大利亚证券交易所提交的文件显示，一项针对其DMX-200候选药物治疗局灶节段性肾小球硬化症患者的ACTION3 III期临床试验数据的外部统计盲法审查证实，该研究具有超过90%的统计功效，能够检测到蛋白尿这一主要终点的治疗效果。 美国食品药品监督管理局（FDA）此前已确认，如果该研究结果为阳性，则DMX-200候选药物（以蛋白尿与安慰剂相比的百分比降低为主要终点）可通过505(b)(1)途径获得传统批准。 周二，该公司股价下跌35%，触及两年来的最低点。
Related Articles
Asia
Raytron Tech's Q1 Profit Surges 228%, Revenue Jumps 71%; Shares Up 5%
Raytron Technology's (SHA:688002) net profit attributable to shareholders in the first quarter surged 228% to 478.7 million yuan from 145.8 million yuan a year earlier, according to a Shanghai bourse filing on Tuesday.Earnings per share soared 211% year on year to 0.98 yuan from 0.32 yuan.Operating revenue jumped 71% to 1.94 billion yuan from 1.14 billion yuan in the prior year.Raytron manufactures uncooled infrared thermal imaging products. Its shares jumped 5% during the afternoon trade.
$SHA:688002
Asia
Jefferies Adjusts Perfect World's Price Target to 19.80 Yuan from 20.60 Yuan, Keeps at Buy
$SHE:002624
Asia
BP Plastics Strikes Off Dormant Unit; Shares Drop 3%
BP Plastics (KLSE:BPPLAS) unit BPPLAS Plantation has been struck off and deemed dissolved from the Companies Commission of Malaysia, according to a Monday Malaysian bourse filing.Shares fell about 3% in Tuesday's midday trade.BPPLAS Plantation was dormant with no future business plans, was dissolved as part of a cost and administrative streamlining exercise.The group said the dissolution will not have a material impact on earnings or net assets.
$KLSE:BPPLAS